Silence Therapeutics (NASDAQ:SLN) Stock Rating Reaffirmed by HC Wainwright

Silence Therapeutics (NASDAQ:SLN – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $80.00 price target on the stock.

Several other research firms have also commented on SLN. Robert W. Baird boosted their price objective on shares of Silence Therapeutics from $50.00 to $53.00 in a research report on Thursday, January 26th. Morgan Stanley started coverage on shares of Silence Therapeutics in a research note on Friday, December 9th. They issued an “equal weight” rating and a $18.00 target price for the company. Finally, Chardan Capital cut their target price on shares of Silence Therapeutics from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday.

Silence Therapeutics Stock Down 3.2 %

Silence Therapeutics stock opened at $8.70 on Friday. Silence Therapeutics has a 52 week low of $7.80 and a 52 week high of $21.32. The firm’s 50-day simple moving average is $12.34 and its 200 day simple moving average is $12.61. The firm has a market capitalization of $260.39 million, a PE ratio of -5.58 and a beta of 0.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in Silence Therapeutics during the 2nd quarter worth approximately $136,000. Millennium Management LLC increased its position in Silence Therapeutics by 19.8% during the 4th quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock worth $266,000 after purchasing an additional 2,879 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Silence Therapeutics during the 4th quarter worth approximately $450,000. UBS Group AG increased its position in Silence Therapeutics by 4.8% during the 4th quarter. UBS Group AG now owns 69,006 shares of the company’s stock worth $1,052,000 after purchasing an additional 3,191 shares in the last quarter. Finally, UBS Oconnor LLC increased its position in Silence Therapeutics by 176.4% during the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company’s stock worth $786,000 after purchasing an additional 50,820 shares in the last quarter.

About Silence Therapeutics

(Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.